Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 53 results for "Mk 5172"

5 Things Merck & Co., Inc.'s Management Wants You to Know
Citybizlist

Merck & Co. (MRK) to Stop Selling Once-Hot Hep C Drug Victreli...

January 21, 2015 By Riley McDermid , BioSpace.com Breaking News Sr. Editor Biopharma behemoth Merck & Co. ( MRK ) will discontinue selling its hepatitis C treatment Victrelis, the company told the U.S. Food and Drug administration this ... ClinicSpace, 1 day ago
[x]  

The Future of Dual Therapy for Hepatitis C Virus

Wei L, Lok AS. Impact of new hepatitis C treatments in different regions of the world. Gastroenterology 146(5), 11451150.e11411144 (2014). Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a ...
 General Medicine eJournal4 days ago
Project Inform

Hepatitis C drug Victrelis (boceprevir) gets pulled from manufacturer

Facebook Twitter Google + Email Print The pharmaceutical company, Merck, has announced that they will stop the manufacture and distribution of their hepatitis C (HCV) protease inhibitor Victrelis by December 2015. As the landscape of HCV ...
 Project Inform4 days ago

Commercial Drone Unmanned Aerial Systems Markets

Next generation commercial drones achieve a complete replacement of existing commercial airfreight delivery systems, they are used for 3D mapping, commercial pipeline observation, border patrol, package delivery, photography, and agriculture are ...
 Electronics.ca Publications1 week ago Commercial Drones: Highways in the Sky, Unmanned Aerial Systems (UAS), Market Shares, Strategies, and Forecasts, Worldwide, 2015 to 2021  Research and Markets1 week ago
Motley Fool

3 Ways Gilead Sciences, Inc. Could Still Be in Big Trouble

Arguably no biotech stock thrilled investors in 2014 more than Gilead Sciences ( NASDAQ: GILD ) . Gilead finished the year up 26%, about double the performance of the broad-market indexes, and the approval and exceptional launch of hepatitis C ...
 Motley Fool2 weeks ago The Hepatitis C Drug Developer That Crushed Gilead Sciences, Inc. in 2014 (Hint: It's Not AbbVie)  Motley Fool1 month ago Sovaldi Can't Sustain The Current Prices Of Gilead Sciences' Stock: Algorithmic And Fundamental Analysis  Seeking Alpha1 month ago
University of Texas

Awards November 2014

Federal Awards Amatruda, James, Children's Hospital of Philadelphia/NIH, COG Solid Malignancy Integrated Translational Science Center Grant, $13,177; Aquino, Victor, Natl Childhood Cancer Fdn/NIH, Primary Immune Deficiency Treatment Consortium - ...
 University of Texas2 weeks ago

MERCK : Studies from Merck & Company Update Current Data on Hepatitis C Virus (Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined...

Studies from Merck & Company Update Current Data on Hepatitis C Virus (Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 ...) ...
 4 Traders2 weeks ago

Specialty drug approvals: Review 
of 2014 and a forecast for 2015

The impact of specialty drugs continues to increase in both drug utilization and spend. In 2012, specialty drug spend accounted for approximately $87 billion, or about 3.1% of national health spend in the United States. In 2020, the forecasted ...
 Pharmacist.com3 weeks ago
Nasdaq

Could Gilead Sciences, Inc. Be a Top Stock in 2015?

GILD data by YCharts Despite last weeks' oil-induced swoon, the S&P 500 is still up by 8% for the year. But don't bother bragging about this to Gilead Sciences shareholders -- through the weekend, Gilead shares had nearly quintupled the broader ...
 Nasdaq1 month ago

A Future Without Hepatitis C?

Bourlière M, Sulkowski MS, Omata M, et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without RBV. Program and abstracts of the 65th annual meeting of the ...
 General Medicine eJournal1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less